Protagonist Therapeutics (PTGX) Free Cash Flow (2015 - 2026)
Protagonist Therapeutics (PTGX) posted Free Cash Flow of -$49.1 million for Q1 2026, down 27.22% sequentially from -$38.6 million in Q4 2025, and down 139.3% YoY from $124.8 million in Q1 2025.
Protagonist Therapeutics (PTGX) Free Cash Flow (2015 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Free Cash Flow for 12 years, with the latest figure at -$49.1 million in Q1 2026.
- Quarterly Free Cash Flow fell 139.3% year-over-year to -$49.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$117.8 million (down 135.13% YoY) and the FY2025 annual result came in at $56.1 million, down 69.32% from the prior year.
- Free Cash Flow declined to -$49.1 million in Q1 2026 per PTGX's latest filing, from -$38.6 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $268.6 million in Q2 2024 and troughed at -$49.1 million in Q1 2026.
- A 5-year average of $636705.9 and a median of -$27.7 million in 2024 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 1116.84% in 2024, down 274.06% in 2024.
- Over 5 years, Free Cash Flow stood at -$31.6 million in 2022, then soared by 153.62% to $16.9 million in 2023, then plunged by 274.06% to -$29.5 million in 2024, then sank by 30.75% to -$38.6 million in 2025, then decreased by 27.22% to -$49.1 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$49.1 million, -$38.6 million, and -$1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 218.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 218.44 Mn |
| Jun 30, 2026 | 218.44 Mn |
| Mar 31, 2026 | -49.05 Mn |
| Mar 31, 2026 | -49.05 Mn |
| Dec 31, 2025 | -38.56 Mn |
| Dec 31, 2025 | -38.56 Mn |
| Sep 30, 2025 | -1.84 Mn |
| Sep 30, 2025 | -1.84 Mn |
| Jun 30, 2025 | -28.34 Mn |
| Jun 30, 2025 | -28.34 Mn |
| Mar 31, 2025 | 124.82 Mn |
| Mar 31, 2025 | 124.82 Mn |
| Dec 31, 2024 | -29.49 Mn |
| Dec 31, 2024 | -29.49 Mn |
| Sep 30, 2024 | -28.63 Mn |
| Sep 30, 2024 | -28.63 Mn |
| Jun 30, 2024 | 268.59 Mn |
| Jun 30, 2024 | 268.59 Mn |
| Mar 31, 2024 | -27.67 Mn |
| Mar 31, 2024 | -27.67 Mn |